- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 29.05. | BIOXYTRAN, INC.: Bioxytran Highlights New Book on Real-Time Monitoring Tissue Oxygenation Relevant to Oxygen Carrier BXT-25 | 1 | GlobeNewswire (USA) | ||
| 15.05. | BIOXYTRAN, INC - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| BIOXYTRAN Aktie jetzt für 0€ handeln | |||||
| 15.04. | BIOXYTRAN, INC - 10-K, Annual Report | - | SEC Filings | ||
| 01.04. | BIOXYTRAN, INC - NT 10-K, Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | - | SEC Filings | ||
| 13.03. | BIOXYTRAN, INC - 8-K, Current Report | 1 | SEC Filings | ||
| 05.03. | Bioxytran Reports Positive Dose Optimization Results, Advances ProLectin-M Toward Phase 3 Trial | - | RTTNews | ||
| 04.03. | BIOXYTRAN, INC.: Bioxytran Announces Positive Dose Optimization Results and Advances Toward Phase 3 Registrational Trial for ProLectin-M | 602 | GlobeNewswire (Europe) | Company Initiates Regulatory Discussions with CDSCO; Plans 408-Patient Pivotal Study Targeting Standard-Risk Several Viral Infected Outpatients BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- Bioxytran... ► Artikel lesen | |
| 02.03. | Bioxytran, Inc. Reports Positive Phase 1b/2a Clinical Study Results for ProLectin-M, a Broad-Range Antiviral Drug in Mild to Moderate COVID-19 | 396 | ACCESS Newswire | BOSTON, MA / ACCESS Newswire / March 2, 2026 / Bioxytran, Inc. (OTCQB:BIXT), a clinical-stage biotechnology company developing carbohydrate-based therapeutics, today announced results from a randomized... ► Artikel lesen | |
| 02.03. | BIOXYTRAN, INC - 8-K, Current Report | 3 | SEC Filings | ||
| 23.02. | Bioxytran, Inc.: Bioxytran Initiates Research Collaboration with University of Georgia to Evaluate Drug Candidate's Ability to Block H5N1 Bird Flu Virus | 540 | ACCESS Newswire | BOSTON, MA / ACCESS Newswire / February 23, 2026 / Bioxytran, Inc. (OTCQB:BIXT), a clinical-stage biotechnology company developing breakthrough antiviral treatments, today announced it has initiated... ► Artikel lesen | |
| 17.02. | Bioxytran, Inc. Announces Commercial Distribution Agreement with Khoury Medical LTD for A-SUQAR Dietary Supplement | 1.569 | ACCESS Newswire | BOSTON, MA / ACCESS Newswire / February 17, 2026 / Bioxytran, Inc. (OTCQB:BIXT) ("Bioxytran" or the "Company"), a biotechnology company developing galectin-targeting carbohydrate technologies with applications... ► Artikel lesen | |
| 11.02. | Bioxytran, Inc: Bioxytran Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance with ProLectin-MBioxytran | 448 | JCN Newswire | BOSTON, Feb 11, 2026 - (ACN Newswire) - Bioxytran, Inc. (OTCQB: BIXT) today announced positive clinical results from its recently completed Phase 2 randomized, double-blind, placebo-controlled, dose-optimization... ► Artikel lesen | |
| 11.02. | BIOXYTRAN, INC - 8-K, Current Report | 1 | SEC Filings | ||
| 04.02. | Bioxytran, Inc.: Bioxytran CEO David Platt, Ph.D. to Present at Noble Capital Markets' Emerging Growth Virtual Equity Conference | 370 | ACCESS Newswire | BOSTON, MA / ACCESS Newswire / February 4, 2026 / Bioxytran, Inc. (OTCQB:BIXT), a clinical-stage biotechnology company focused on the development of novel carbohydrate-based therapeutics, today announced... ► Artikel lesen | |
| 02.02. | Bioxytran, Inc.: Bioxytran and University of Minnesota Launch Sponsored Research Collaboration to Advance Novel Carbohydrate-Based Therapeutics | 373 | ACCESS Newswire | NEEDHAM, MA / ACCESS Newswire / February 2, 2026 / Bioxytran, Inc. (OTCQB:BIXT) ("Bioxytran" or the "Company"), a clinical-stage biotechnology company developing platform technologies spanning glycovirology... ► Artikel lesen | |
| 29.01. | Bioxytran, Inc.: Bioxytran Provides Corporate Update Highlighting Momentum Across Its Multi-Platform Pipeline | 397 | ACCESS Newswire | Company reiterates focus on advancing ProLectin-M under an active FDA IND and progressing oxygen-transport programs for stroke and neurodegenerative diseases NEEDHAM, MA / ACCESS Newswire / January... ► Artikel lesen | |
| 05.01. | BIOXYTRAN, INC - 8-K, Current Report | - | SEC Filings | ||
| 29.10.25 | Bioxytran, Inc.: Bioxytran Completes Randomized Clinical Trial For its Broad-Spectrum Antiviral Drug | 154 | GlobeNewswire (Europe) | Data from the dose optimization trial expected soonProLectin-M is positioned as the first oral antiviral sugar chemistry drug BOSTON, MASSACHUSETTS, Oct. 29, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC.... ► Artikel lesen | |
| 15.08.25 | Bioxytran, Inc.: Bioxytran Unveils Revolutionary Precision Diagnostics on Tissue Oxygenation | 477 | GlobeNewswire (Europe) | Game changer for stroke, Alzheimer's, and beyond Shifting from peripheral to tissue-specific oxygenation monitoring BOSTON, MASSACHUSETTS, Aug. 15, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB:... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| KYMERA THERAPEUTICS | 108,12 | 0,00 % | Top Biotech Gainers: TECH Bought Out, MSLE On Watch, KYMR Hits New High, What's The Buzz At SLS? | OTTAWA (dpa-AFX) - Today's top gainers in the biotech space include Bio-Techne, following acquisition news; Satellos Bioscience, gearing up to present new DMD data next month; and Kymera, which... ► Artikel lesen | |
| BICARA THERAPEUTICS | 26,870 | 0,00 % | Bicara Therapeutics Inc.: Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-ß Inhibition in 1L R/M HPV-Negative HNSCC | At a median follow-up of three years, 1500mg of ficerafusp alfa weekly in combination with pembrolizumab demonstrated an estimated 31% overall survival, approximately doubling OS compared to a... ► Artikel lesen | |
| DYNE THERAPEUTICS | 20,940 | 0,00 % | Dyne Therapeutics stock initiated at buy by TD Cowen on platform | ||
| IMMIX BIOPHARMA | 9,980 | 0,00 % | Immix Biopharma, Inc.: Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2 | - Of first 20 patients, all four MRD-negative patients have converted to complete response (CR) - - CR rate now 95% (19 of 20 patients) - - All CRs reached within 1 year of follow-up post-dosing... ► Artikel lesen | |
| ALLOGENE THERAPEUTICS | 2,130 | 0,00 % | Allogene Therapeutics, Inc. - 8-K, Current Report | ||
| APOGEE THERAPEUTICS | 132,62 | +0,05 % | Apogee Therapeutics: Hier dürfte zum US-Handelsstart heute die Post abgehen! | AbbVie steht laut einem Bericht kurz vor der Übernahme von Apogee Therapeutics für rund 10,9 Milliarden US-Dollar in bar. Der mögliche Aufschlag liegt bei etwa 60 Prozent. Weil die US-Börsen am Freitag... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 94,81 | 0,00 % | Inhibrx Biosciences, Inc.: Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma | No filing review issues identified by FDA with PDUFA goal date set for April 14, 2027
If Approved, Ozekibart Would Be the First and Only FDA-Approved Treatment... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 327,29 | -0,15 % | Praxis Precision Medicines, Inc. - 8-K, Current Report | ||
| SAB BIOTHERAPEUTICS | 3,800 | 0,00 % | Barclays initiates SAB Biotherapeutics stock at Overweight, PT $13 | ||
| AMYLYX PHARMACEUTICALS | 17,790 | 0,00 % | Amylyx Pharmaceuticals, Inc.: Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026 | Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) ("Amylyx" or the "Company") today announced the presentation of data from its first-in-human, dose-ranging Phase 1 LUMINA trial of AMX0114 at the European... ► Artikel lesen | |
| QIAGEN | 34,315 | -0,59 % | DZ BANK stuft QIAGEN NV auf 'Kaufen' | FRANKFURT (dpa-AFX Analyser) - Die DZ Bank hat den fairen Wert für Qiagen von 38 auf 40 Euro angehoben und die Einstufung auf "Kaufen" belassen. Das Thema Künstliche Intelligenz (KI) sei für den Life-Science-Zuliefersektor... ► Artikel lesen | |
| TANGO THERAPEUTICS | 31,445 | -0,08 % | Tango Therapeutics, Inc.: Tango Therapeutics Appoints Robert Azelby to Board of Directors | BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer... ► Artikel lesen | |
| PHATHOM PHARMACEUTICALS | 10,720 | 0,00 % | Phathom Pharmaceuticals schließt Rekrutierung für Phase-2-Studie zu EoE ab | ||
| PROKIDNEY | 1,830 | 0,00 % | ProKidney Appoints Kenneth Locke as Chief Technical Officer | WINSTON-SALEM, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease... ► Artikel lesen | |
| HUMACYTE | 0,709 | 0,00 % | Humacyte, Inc: Humacyte ATEV Met Superiority Primary Endpoint Compared to Standard of Care AV Fistula in Interim Analysis of V012 Phase 3 Study in Female Dialysis Access Patients | - Humacyte plans to file a supplemental Biologic License Application (BLA) with the Food and Drug Administration (FDA) during the second half of 2026 - - The ATEV met V012's primary endpoint and was... ► Artikel lesen |
BIOXYTRAN INC gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOXYTRAN INC finden Sie auf Wallstreet Online.